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Abstract
Aims Heart failure (HF) and atrial fibrillation (AF) may coexist and influence each other. However, characteristics, anticoag-
ulant treatment, and outcomes of contemporary AF patients with concurrent HF are ill-defined. This study analyses character-
istics, treatment, and 2 year outcomes in newly diagnosed Global Anticoagulant Registry in the FIELD-Atrial Fibrillation
(GARFIELD-AF) patients with vs. without HF.
Methods and results GARFIELD-AF is the world’s largest observational AF patient study. At enrolment, 11 758 of 52 072
patients (22.6%) had HF; 76.3% were New York Heart Association class II–III. Patients with HF had comparable demographics,
blood pressure, and heart rate but more likely had permanent (15.6% vs. 11.9%) or persistent AF (18.9% vs. 13.8%), acute
coronary syndromes (16.7% vs. 8.9%), vascular disease (40.8% vs. 20.2%), and moderate-to-severe chronic kidney disease
(14.6% vs. 9.0%) than those without. Anticoagulant prescription was similar between the two groups. At 2 year follow-up, pa-
tients with HF showed a greater risk of all-cause mortality [hazard ratio (HR), 2.06; 95% confidence interval (CI), 1.91–2.21;
P < 0.0001], cardiovascular mortality (HR, 2.91; 95% CI, 2.58–3.29; P < 0.0001), acute coronary syndromes (HR, 1.25; 95%
CI, 1.02–1.52; P = 0.03), and stroke/systemic embolism (HR, 1.24; 95% CI, 1.07–1.43; P = 0.0044). Major bleeding rate was
comparable (adjusted HR, 1.00; 95% CI, 0.84–1.18; P = 0.968). Among patients without HF at baseline, incidence of new HF
was low [0.69 (95% CI, 0.63–0.75) per 100 person-years], whereas propensity to develop worsening HF was higher in those
with HF [1.62 (95% CI, 1.45–1.80) per 100 person-years].
Conclusions Patients with AF and HF have a high risk of all-cause and cardiovascular mortality and stroke/systemic embolism
and may develop worsening HF.
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Introduction
Atrial fibrillation (AF) and heart failure (HF) may coexist and in-
teractwith each other inmany patients.1Considerable evidence
points to a high risk for incident AF in HF patients, which may
confer a negative prognostic impact.2–8 However, most knowl-
edge of HF in AF has been obtained by focusing on HF patients
who have developed AF during the course of their index disease
through retrospective analyses of historical randomized clinical
trials or registries.3,4,9 Therefore, there are inherent limitations
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due to the use of strict inclusion criteria in clinical studies and
outdatedmanagement practices with respect to both HF (drugs
and device implant) and AF [new oral anticoagulant (NOAC)].
Furthermore, knowledge about AF patients who develop HF is
limited, as recently reviewed by Ling et al.10
To gain further insights into the impact of HF on AF pa-
tients, we leveraged the Global Anticoagulant Registry in
the FIELD-Atrial Fibrillation (GARFIELD-AF). This registry is
a large, prospective, multinational registry of over 50 000
AF patients followed for at least 2 years, designed to
reflect contemporary clinical practice in a global population.
As studies regarding the association of AF and HF have typ-
ically focused upon patients with a primary diagnosis of HF,
the key interests of this study were to evaluate the clinical
characteristics and antithrombotic treatment patterns of
patients specifically with newly diagnosed AF who present
with or without co-morbid HF. Using this large registry,
we aim to establish the impact of concomitant HF upon
long-term outcomes in AF patients, particularly all-cause




The design of the GARFIELD-AF registry was reported
previously.11,12 Briefly, men and women aged over 18 years
with AF were diagnosed according to standard local proce-
dures within the previous 6 weeks, with at least one
non-prespecified risk factor for stroke as judged by the local
investigator, and no valvular diseases were eligible for
inclusion.12 Patients were enrolled prospectively and consec-
utively at 1317 sites in 35 countries. If random site selection
did not generate the required number of sites in a given
country, the national lead investigator recommended addi-
tional sites (18 of 1317 sites). The sites represent different
care settings in each participating country.
Ethics
Independent ethics committee and hospital-based institu-
tional review boards approved the study. The registry was
conducted in accordance with the principles of the
Declaration of Helsinki, local regulatory requirements, and
International Conference on Harmonization–Good
Pharmacoepidemiological and Clinical Practice guidelines.
All patients provided written informed consent to
participate, and their confidentiality and anonymity were
maintained.
Procedures and outcome measures
Baseline characteristics were collected at inclusion in the
registry.11,12 Components of the CHA2DS2-VASc
13,14 and
HAS-BLED15 risk stratification schemes were documented;
the latter score was calculated excluding fluctuations in inter-
national normalized ratio. Follow-up data on treatments and
outcomes were captured on electronic case report forms
(eCRFs) at four-monthly intervals up to 12months. Submitted
data were examined for completeness and accuracy by the
coordinating centre (Thrombosis Research Institute London,
UK). One-fifth of eCRFs (20%) were monitored against source
documentation.12 Data for the present analysis were
extracted from the study database in November 2018.
Definitions
Heart failure was defined as left ventricular ejection fraction
(LVEF) <40%, history of HF, or physician diagnosis of HF at
baseline. Severity of HF was categorized according to the
New York Heart Association (NYHA) functional classification.
Worsening HF was defined as progressive or acute
decompensation of previously stable HF or post-enrolment
re-stratification into higher-severity NYHA functional classifi-
cation, as determined by treating physicians. Vascular disease
included coronary artery disease with or without history of
acute coronary syndromes (ACS) and/or peripheral artery
disease. Chronic kidney disease (CKD) was classified according
to National Kidney Foundation guidelines16 into moderate-to-
severe (Stages 3–5), mild (Stages 1 and 2), or none.
Statistical analysis
Baseline characteristics are described with frequencies (per-
centage) for categorical variables and medians (interquartile
range) for continuous variables. Incidence rates for the first
occurrence of outcome events (per 100 person-years) were
estimated by Poisson model with number of events as depen-
dent variable and log of time as offset, that is, a covariate
with known coefficient of 1. Hazard ratios (HRs) with 95%
confidence intervals (CIs) for outcome events in HF vs.
no-HF groups were calculated as unadjusted and adjusted
results using Cox proportional hazards models. Adjustment
factors were as follows: sex; race/ethnicity; age with spline
knots at 48, 65, 79, and 88 years; body mass index (BMI); oral
anticoagulant therapy at baseline; type of AF; hypertension;
history of bleeding; vascular disease; prior stroke/transient
ischaemic attack; moderate-to-severe CKD; diabetes; smoking
status; and heavy alcohol intake. Five imputed datasets were
used to account for missing data when calculating HRs.
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A total of 52 072 AF patients (M/F, 55.8/44.2%; no-HF
group, n = 40 314; mean age, 69.5 years; HF group,
n = 11 758; mean age, 70.1 years) were followed
prospectively for 2 years; their baseline characteristics
and medications are summarized in Table 1 and Figure 1.
Approximately two-third of cases with and without HF
had either paroxysmal or unclassified AF. Numerically, the
link with HF was stronger for permanent/persistent than
paroxysmal AF. In no-HF and HF groups, median CHA2DS2-
VASc score (interquartile range) was 3.0 (2.0–4.0) and 4.0
(3.0–5.0), respectively; HAS-BLED score was 1.0 (1.0–2.0)
in both groups. Prior stroke/transient ischaemic attack
was documented in 11.6% and 10.9%, respectively; history
of bleeding in 2.4% and 3.0%; and type 2 diabetes in
20.5% and 23.4%. Background therapy and implementation
of guideline-recommended practice were consistent among
all patients (Table 1). Most HF patients (76%) were catego-
rized as NYHA class II–III.
Table 1 Patient demographics and clinical characteristics
Parameter No HF (n = 40 314) HF (n = 11 758) P-valuea
Male, n (%) 22 344 (55.4) 6720 (57.2) 0.0009
Age (years), median (IQR) 71.0 (63.0–78.0) 71.0 (62.0–79.0) 0.0002
Ethnicity, n (%) <0.0001
Afro-Caribbean 186 (0.5) 57 (0.5)
Asian (not Chinese) 8926 (22.1) 2633 (22.4)
Caucasian 24 692 (61.2) 7333 (62.4)
Chinese 2138 (5.3) 605 (5.1)
Hispanic/Latino 2689 (6.7) 707 (6.0)
Other 594 (1.5) 233 (2.0)
Unknown 1089 (2.7) 190 (1.6)
BMI (kg/m2), median (IQR) 27.0 (24.0–30.0) 27.0 (24.0–32.0) <0.0001
SBP (mmHg), mean (SD) 133.9 (19.6) 132.0 (20.4) <0.0001
DBP (mmHg), mean (SD) 79.6 (12.7) 80.1 (13.6) 0.0009
Heart rate (b.p.m.), mean (SD) 89.8 (26.7) 92.5 (26.8) <0.0001
LVEF (%), median (IQR) 60.0 (55.0–65.0) 47.0 (35.0–58.0) <0.0001
Type of AF, n (%) <0.0001
Permanent 4798 (11.9) 1837 (15.6)
Persistent 5549 (13.8) 2218 (18.9)
Paroxysmal 11 894 (29.5) 2421 (20.6)
New 18 073 (44.8) 5282 (44.9)
CHA2DS2-VASc score, median (IQR) 3.0 (2.0–4.0) 4.0 (3.0–5.0) <0.0001
HAS-BLED score, median (IQR) 1.0 (1.0–2.0) 1.0 (1.0–2.0) <0.0001
Medical history, n (%)
ACS 3589 (8.9) 1956 (16.7) <0.0001
Vascular disease 8072 (20.2) 4761 (40.8) <0.0001
Moderate-to-severe CKD 3639 (9.0) 1721 (14.6) <0.0001
Stroke/TIA 4680 (11.6) 1281 (10.9) 0.0388
Prior bleeding 965 (2.4) 353 (3.0) 0.0002
Diabetes (type 1 or 2) 8687 (21.5) 2868 (24.4) <0.0001
Stroke prophylaxis <0.0001
VKA 12 061 (30.3) 3318 (28.9)
VKA + AP 3308 (8.3) 1519 (13.2)
FXA 6851 (17.2) 1732 (15.1)
FXA + AP 1400 (3.5) 496 (4.3)
DTI 2410 (6.0) 612 (5.3)
DTI + AP 465 (1.2) 162 (1.4)
AP alone 8116 (20.4) 2655 (23.1)




13 433 (50.6) 5144 (65.4) <0.0001
Beta-blocker 14 680 (55.3) 5168 (65.7) <0.0001
Diuretic agent 6864 (25.9) 4382 (55.7) <0.0001
Digoxin/digitalis 1767 (6.7) 1381 (17.6) <0.0001
Aldosterone antagonist 849 (3.2) 1463 (18.6) <0.0001
ACS, acute coronary syndromes; AF, atrial fibrillation; AP, antiplatelet; BMI, body mass index; CKD, chronic kidney disease; DTI,
direct thrombin inhibitor; FXA, factor Xa antagonist; HF, heart failure; IQR, interquartile range; LVEF, left ventricular ejection fraction;
SBP/DBP, systolic/diastolic blood pressure; SD, standard deviation; TIA, transient ischaemic attack; VKA, vitamin K antagonist.
aFor categorical variables, P-values were obtained from a χ2 test or Fisher’s exact test, as appropriate. For continuous variables, P-values
were obtained from a t-test or a Wilcoxon–Mann–Whitney test, as appropriate.
bMeasured in GARFIELD-AF cohorts 3–5 (no HF, n = 26 526; HF, n = 7867).
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Heart failure was defined according to LVEF, current HF, or
a history of HF. Of patients with HF, 73.4% had recorded LVEF
measurements, compared with 54.1% of patients without HF.
To assess the potential reporting bias introduced by this dif-
ference, patients were also checked according to the pres-
ence of a new HF diagnosis at baseline or a history of HF
only. Under these criteria, 10 347 patients had HF, of which
70% had an LVEF measurement, whereas the remaining
no-HF patients had LVEF measure in 55.6% of cases. Although
AF patients with and without concomitant HF were compara-
ble in terms of sex, age, ethnicity, BMI, blood pressure, heart
rate, and medical history, some of their clinical characteristics
were significantly different: HF patients more frequently had
history of ACS (16.7% vs. 8.9%), vascular disease (40.8% vs.
20.2%), and moderate-to-severe CKD (14.6% vs. 9.0%; all
P < 0.001). Moreover, patients with HF were more likely to
have permanent AF (15.6% vs. 11.9%) or persistent AF
(18.9% vs. 13.8%).
Antithrombotic and heart failure therapies
A similar proportion of HF and no-HF patients received
anticoagulation (68.2% vs. 66.5%; Figure 1). HF patients less
frequently received no treatment (8.7% vs. 13.2%) and were
more likely prescribed antiplatelet therapy, either alone
(23.1% vs. 20.4%) or in combination with anticoagulant
(18.9% vs. 13.0%). On the other hand, higher proportions of
HF than no-HF patients received cardiovascular agents across
all major drug classes (Table 1).
Clinical characteristics and treatment provided
across the New York Heart Association functional
categorizations
Clinical characteristics of patients stratified by the presence
and severity of HF (NYHA I–II or III–IV) are displayed in
Table 2. Within the HF group, most clinical characteristics
were not markedly different across patients stratified by
NYHA functional classification I–II or III–IV, although ACS,
CKD, and vascular disease were more frequently observed
in those with NYHA functional class III–IV.
Initial antithrombotic treatment provided to AF patients
without HF and those with HF stratified according to NYHA
functional class I–IV is shown in Figure 2. Although the number
of patients categorized as NYHA functional class IV is rather
small (n = 418), these individuals were clearly undertreated;
they were less likely to receive anticoagulation and more likely
to receive antiplatelet agents only or no antithrombotic
treatment than AF patients with less severe or no HF.
Outcomes at 2 year follow-up
Among AF patients without HF at baseline, de novo HF
developed in 517 individuals (1.3%) during 2 year follow-up,
Figure 1 Baseline therapy—heart failure vs. no heart failure: baseline
treatment with anticoagulants/antiplatelet agents. AP, antiplatelet; DTI,
direct thrombin inhibitor; FXa, factor Xa inhibitor; HF, heart failure;
VKA, vitamin K antagonist.
Table 2 Baseline clinical characteristics in patients stratified by the presence and severity of heart failure
Parameter
No HF




(n = 3057) P-valuea
Sex male, n (%) 22 344 (55.4) 3539 (54.8) 1682 (55.0) 0.6259
Age (years), median (IQR) 71.0 (63.0–78.0) 71.0 (62.0–79.0) 72.0 (63.0–80.0) <0.0001
LVEF (%), median (IQR) 60.0 (55.0–65.0) 45.0 (43.0–61.0) 45.0 (35.0–55.0) <0.0001
Medical history, n (%)
Hypertension 30 519 (75.9) 5205 (80.7) 2366 (77.5) <0.0001
ACS 3589 (8.9) 934 (14.6) 639 (21.0) <0.0001
Vascular disease 8072 (20.2) 2543 (39.6) 1478 (48.7) <0.0001
Moderate-to-severe CKD 3639 (9.0) 831 (12.9) 634 (20.7) <0.0001
CHA2DS2-VASc, median (IQR) 3.0 (2.0–4.0) 4.0 (3.0–5.0) 4.0 (3.0–5.0) <0.0001
HAS-BLED, median (IQR) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 2.0 (1.0–2.0) <0.0001
ACS, acute coronary syndromes; CKD, chronic kidney disease; HF, heart failure; IQR, interquartile range; LVEF, left ventricular ejection frac-
tion; NYHA, New York Heart Association.
aFor categorical variables, P-values were obtained from a χ2 test or Fisher’s exact test, as appropriate. For continuous variables, P-values
were obtained from a one-way ANOVA or a Kruskal–Wallis test, as appropriate.
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corresponding to a rate of 0.69 (95% CI, 0.63–0.75) per 100
person-years. However, in the HF cohort, worsening HF was
seen in 334 individuals (2.8%), corresponding to a rate of
1.62 (95% CI, 1.45–1.80) per 100 person-years.
In HF vs. no-HF patients, there were significantly (all
P < 0.0001) higher incidence rates (95% CI; per 100
person-years) of all-cause death [6.93 (6.59–7.30) vs. 2.95
(2.83–3.08)], cardiovascular death [3.10 (2.87–3.34) vs. 0.87
(0.81–0.94)], non-cardiovascular death [2.08 (1.89–2.28)
vs. 1.29 (1.21–1.37)], ACS [0.92 (0.80–1.06) vs. 0.54
(0.49–0.60)], and stroke/systemic embolism (SE) [1.43
(1.28–1.60) vs. 1.02 (0.95–1.09)]. Rates of major bleeding
were similar in the two groups [1.03 (0.90–1.18) vs. 0.96
(0.89–1.03); P = 0.4127].
Kaplan–Meier curves depicting the probability of avoiding
all-cause death, stroke/SE, and ACS in the HF and no-HF
groups over 2 years are shown in Figure 3. In particular, sur-
vival curves for all-cause mortality in the two groups immedi-
ately began to diverge, with a significantly higher risk of this
event noted in HF than no-HF patients throughout the study.
Risk of stroke/SE and ACS was also higher in the HF group vs.
the no-HF group, albeit delayed, reaching statistical signifi-
cance after approximately 3 and 6 months, respectively.
Adjusted HRs for all outcome parameters are presented in
Figure 4. Notably, risk of death by any cause was twice, and
cardiovascular death thrice, as likely in HF vs. no-HF patients
over 2 years.
Two-year outcomes in patients stratified by the presence
of HF and NYHA functional class I–IV are shown in Figure 5.
A clear correlation was noted between increasingly
severe HF and progressively higher incidence rates of
adverse outcomes. Especially, the rates of all-cause death,
cardiovascular death, and non-cardiovascular death rose
exponentially and were almost twice as high in each succes-
sive NYHA functional class from I to IV. In patients with no
HF who died, cause of death was cardiovascular related in
less than one-third of cases and non-cardiovascular in nearly
half of cases (others unknown), whereas in patients with
NYHA functional class III–IV who died, this trend was re-
versed (cardiovascular mortality, 47.8%; non-cardiovascular
mortality, 27.7%).
Patients with no HF at baseline were at a low risk of going
on to develop HF [incidence rate, 0.69 (95% CI, 0.63–0.75)]; in
those with HF, risk of worsening HF increased with higher
NYHA functional class from I [rate of HF worsening, 1.16
(95% CI, 0.84–1.58)] to IV [HF worsening, 2.15 (95% CI,
1.27–3.63)].
New heart failure
Of the 40 314 patients with ‘no HF’, 517 (1.3%) developed
new HF during the study compared with 39 797 (98.7%)
who did not. Patients with new HF were less often male
and slightly older than those without (49.5% and 75.0 years
vs. 55.5% and 71.0 years). Paroxysmal and persistent AF were
more common in patients with new HF than in those without
(29.6%; 13.8% vs. 20.9%; 16.1%, respectively), whereas per-
manent AF was less common in new HF patients (16.1% vs.
11.9%, respectively). Of patients with new HF, 79.6% were
Caucasian and 12.2% were Asian, compared with 62.7% and
28.4% of those without new HF. Clinical characteristics dif-
fered between these two groups. Patients who developed
new HF more often had ACS, vascular disease, diabetes, and
Figure 2 Antithrombotic treatment patterns in patients stratified by the presence and severity of heart failure (HF). HF severity was categorized
according to the New York Heart Association (NYHA) functional classification. AP, antiplatelet; DTI, direct thrombin inhibitor; FXa, factor Xa inhibitor;
VKA, vitamin K antagonist.
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Figure 3 Cumulative incidence rates of (A) all-cause mortality, (B) stroke/SE, and (C) ACS in atrial fibrillation patients. Rates are stratified by the
presence and absence of heart failure at baseline over a 2 year observation period. ACS, acute coronary syndromes; MI, myocardial infarction; SE,
systemic embolism.
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moderate-to-severe CKD (13.2%, 28.2%, 26.1%, and 20.7%,
respectively), compared with those who did not develop HF
(8.9%, 20.1%, 21.5%, and 10.1%, respectively) (Table 3).
Of patients with no HF, those who developed new HF
during follow-up were less likely to receive vitamin K
antagonists at baseline than those who did not develop
new HF (19.0% vs. 28.0%). Conversely, those who developed
new HF were slightly more likely to have received AP
therapy alone (25.5% vs. 20.3%). NOAC usage was compara-
ble (Table 3).
Discussion
This analysis of GARFIELD-AF registry on over 50 000 patients
provides useful insights into the complex and often challeng-
ing condition of de novo AF with co-morbid HF at baseline.
GARFIELD-AF is the largest registry to date investigating the
impact of concurrent HF in AF patients, providing global
observational data in a real-world clinical setting. Several im-
portant findings emerged. First, the present data extend pre-
vious observations to a more contemporary, multi-country,
Figure 5 Unadjusted and adjusted 2 year outcomes [hazard ratios vs. no heart failure (HF)] in patients stratified by severity of HF. Severity of HF is
stratified via the New York Heart Association (NYHA) functional classes I–IV. ACM, all-cause mortality; ACS, acute coronary syndromes; CI, confidence
interval; CV, cardiovascular; MI, myocardial infarction; SE, systemic embolism.
Figure 4 Major adverse outcomes in atrial fibrillation patients with heart failure vs. without heart failure (reference): adjusted hazard ratios (HRs). This
figure is the central illustration of the manuscript. ACS, acute coronary syndromes; CI, confidence interval; MI, myocardial infarction; SE, systemic
embolism.
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and multi-setting practice, showing that approximately one
quarter of patients with newly diagnosed AF present with
HF. Second, this study demonstrates that the rate of
anticoagulation was similar, or higher, in AF patients with
concurrent HF compared with those without HF and that pre-
scription rates of NOACs were comparable. Third, although
most demographics and baseline characteristics were similar
in the two groups, classical risk factors were different be-
tween HF and no-HF patients. Those with HF had more ACS
and CKD and were twice as likely to have history of vascular
disease. Fourth, AF patients with HF experienced substan-
tially higher rates of adverse outcomes than those without
HF. It is noteworthy that although HF patients received more
cardiovascular drugs than no-HF individuals, their prescrip-
tion rates of beta-blockers and renin-angiotensin-aldosterone
system inhibitors were suboptimal, and this may have con-
tributed to worse outcomes. Finally, at odds with common
beliefs, among patients with AF and no HF at baseline, inci-
dence of new HF over 2 year follow-up was low. Worsening
HF, on the other hand, was more often observed in AF
patients in higher NYHA class.
Individually, AF and HF are the two biggest epidemics in
cardiology.17 In the USA, AF affects approximately 2% of the
population aged under 65 years and 9% of those aged over
65.10,18 The prevalence rates of these two conditions are
expected to increase in future due to aging populations and
higher survival rates among people with cardiovascular dis-
eases as better therapies emerge. Importantly, AF and HF
are linked aetiologically: many AF patients also have HF, and
the likelihood of developing AF increases with severity of
HF.18 The Euro Heart Study on AF9 estimated that one-third
of AF patients also have HF, a slightly higher prevalence than
that observed in the present contemporary patient cohort. In
distinction to the important role of HF in AF, a range of
further critical risk factors are independently responsible for
triggering AF in the absence of HF. Non-exhaustively,
examples include vascular disease such as hypertension,
atherosclerosis, the presence of pulmonary vein foci, and
Table 3 Baseline characteristics of atrial fibrillation patients who developed new heart failure vs. those who did not
Parameter No new heart failure (n = 39 797) New heart failure (n = 517) P-valuea
Male, n (%) 22 088 (55.5) 256 (49.5) 0.0065
Age (years), median (IQR) 71.0 (63.0–78.0) 75.0 (68.0–80.0) <0.0001
Ethnicity, n (%) <0.0001
Caucasian 24 301 (62.7) 391 (79.6)
Hispanic/Latino 2660 (6.9) 29 (5.9)
Asian 11 004 (28.4) 60 (12.2)
Afro-Caribbean/mixed/other 769 (2.0) 11 (2.2)
BMI (kg/m2), median (IQR) 26.8 (23.9; 30.4) 28.4 (24.6; 32.9) <0.0001
SBP (mmHg), mean (SD) 132.0 (120.0; 145.0) 135.0 (120.0; 145.0) 0.4284
DBP (mmHg), mean (SD) 80.0 (70.0; 88.0) 80.0 (70.0; 90.0) 0.8864
Heart rate (b.p.m.), mean (SD) 83.0 (70.0; 104.0) 88.0 (72.0; 112.0) 0.0024
Type of AF, n (%) <0.0001
Permanent 4715 (11.9) 83 (16.1)
Persistent 5492 (13.8) 57 (11.0)
Paroxysmal 11 786 (29.6) 108 (20.9)
New 17 804 (44.7) 269 (52.0)
CHA2DS2-VASc score, median (IQR) 3.0 (2.0–4.0) 4.0 (3.0–4.0) <0.0001
HAS-BLED score, median (IQR) 1.0 (1.0–2.0) 2.0 (1.0–2.0) <0.0001
Medical history, n (%)
ACS 3521 (8.9) 68 (13.2) 0.0007
Vascular disease 7926 (20.1) 146 (28.2) <0.0001
Carotid occlusive disease 1159 (3.0) 18 (3.5) 0.4537
VTE 1003 (2.5) 19 (3.7) 0.0966
Stroke/TIA/SE 4520 (11.4) 67 (13.1) 0.2525
Prior bleeding 942 (2.4) 23 (4.5) 0.0021
Hypertension 30 107 (75.9) 412 (79.8) 0.0361
Hypercholesterolaemia 15 937 (41.3) 200 (39.5) 0.4202
Diabetes 8552 (21.5) 135 (26.1) 0.0111
Cirrhosis 197 (0.5) 5 (1.0) 0.1375
Moderate-to-severe CKD 3547 (10.1) 92 (20.7) <0.0001
Dementia 488 (1.2) 5 (1.2) 0.8938
Treatment <0.0001
VKA ± AP 11 030 (28.0) 96 (19.0)
NOAC ± AP 15 163 (38.5) 206 (40.7)
AP alone 7987 (20.3) 129 (25.5)
None 5166 (13.1) 75 (14.8)
ACS, acute coronary syndromes; AF, atrial fibrillation; AP, antiplatelet; BMI, body mass index; CKD, chronic kidney disease; IQR, interquar-
tile range; NOAC, new oral anticoagulant; SBP/DBP, systolic/diastolic blood pressure; SD, standard deviation; SE, systemic embolism; TIA,
transient ischaemic attack; VKA, vitamin K antagonist; VTE, venous thromboembolism.
aFor categorical variables, P-values were obtained from a χ2 test or Fisher’s exact test, as appropriate. For continuous variables, P-values
were obtained from a t-test or a Wilcoxon–Mann–Whitney test, as appropriate.
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myocardial infarction. Diabetes, renal dysfunction, and demo-
graphic characteristics such as BMI, sex, and age are also
closely linked to an increasing rate of incident AF.
Risk factors for AF and HF greatly overlap,19 and
AF-induced cardiomyopathy can lead to decline of left ven-
tricular function leading to HF.20 Given these common patho-
physiological aspects, it has been postulated ‘AF begets HF,
and HF begets AF’.21 Specific pathophysiological changes by
which AF and HF contribute to their co-development are
complex and not fully understood.19 Cardiac remodelling, ac-
tivation of neurohormonal compensatory mechanisms, and
impairment of left ventricular function have been posited as
possible reasons for how AF and HF can cause and exacerbate
each other. In our registry, most patients with newly diag-
nosed AF and HF had preserved LVEF; increased heart rate
and loss of atrial contraction in AF may have contributed to
development of HF. It is clear, however, that patients with
concurrent AF and HF have worse prognosis than those with
either condition alone, as confirmed by the present analysis
and in a previous report on GARFIELD-AF patients with HF
associated with ischaemic cardiomyopathy.22
Both AF and HF are major causes of stroke.23,24 Indeed, the
widely accepted AF-related stroke risk index CHA2DS2-VASc
includes 1 point for the presence of HF.13,14 Subgroup
analyses of the landmark trials of NOACs vs. warfarin
revealed that these drugs work equally well at preventing
stroke/SE in AF patients with and without HF, with similar
rates of bleeding.25–28 In the present study, patients with
AF and co-morbid HF had an approximately 30% higher risk
of stroke/SE compared with no-HF patients, a statistically
significant difference (P < 0.001), despite their receiving
equivalent anticoagulation regimens. This finding suggests
that even in contemporary medicine and after the introduc-
tion of NOACs, HF in itself remains a major risk factor for
stroke and that patients with concomitant AF and HF should
be closely monitored to reduce risk and optimize treatment.
In this analysis, new HF arising during follow-up was seen
in only 517 of the 40 314 AF patients (1.3%). This apparently
contrasts with reports from the Framingham study, in which
16% of patients developed incident HF after AF diagnosis. It
should be noted, however, that the Framingham study
followed only 1737 AF patients with no HF at baseline, as op-
posed to the over 40 000 in GARFIELD-AF. More importantly,
whereas GARFIELD-AF patients were followed over 2 years,
the 277 cases of incident HF in the Framingham study were
accrued over a much longer period of time: between 1980
and 2012. Therefore, incidence rate per person-year was
actually quite small. In support of the present findings, similar
results were reported by the US-based ORBIT-AF registry of
AF patients, in whom de novo HF developed in only a few
per cent over 2 years of observation.29 Similar to the
ORBIT-AF registry, new HF was associated with a slightly
older cohort of patients and was more frequently linked to
adverse clinical characteristics, including vascular disease
and moderate-to-severe CKD. Age, vascular disease, and
renal dysfunction are important independent risk factors for
HF, possibly indicating the cause of incident HF in these 517
patients.
The present study also clearly shows that, for patients who
already have HF, newly diagnosed AF is indeed an influencing
factor associated with clinical deterioration of HF. These
findings confirm and extend a recent report from a retrospec-
tive analysis of PARADIGM-HF and ATMOSPHERE databases,
which shows that new-onset AF was associated with a
significantly increased risk of HF rehospitalization.30
This study has limitations. The definition of HF adopted
herein (i.e. LVEF <40% or history of HF as adjudged by signs
and symptoms) was conceived when the GARFIELD-AF study
was designed. However, it tallies well with those suggested
by international medical societies; indeed, both the 2013
American College of Cardiology Foundation/American Heart
Association guidelines31 (most recently updated 201732) and
the 2016 European Society of Cardiology guidelines33 broadly
classify HF patients as having preserved or reduced ejection
fraction with a cut-off value for the latter ≤40%, on the basis
that this was selection criterion used in clinical trials demon-
strating efficacy of drug therapies. Importantly, the propor-
tion of patients with a recorded LVEF measurement was
notably lower in those without concurrent HF. It is possible
that this may introduce a potential reporting bias, whereby
those without HF may have been incorrectly assigned to this
group simply due to the lack of LVEF measurement. However,
LVEF was not the only criterion to allocate patients to the ‘no-
HF’ group, as we also recorded history of HF, or current diag-
nosis of HF: reassessing the assignment of patients into each
group according to a history of HF or current HF only shows
that a similar number of patients were characterized with
HF. Additionally, the proportion of patients in the HF group
who had measured LVEF remained substantially higher than
in the no-HF patient group. It is therefore likely that the
disparity in recorded LVEF measurements may have arisen
as patients who presented with no history nor evidence for
HF were not considered for measurement of LVEF. A further
limitation of this study is that ventricular filling pressures
were not collected for this cohort, and thus, we are unable
to establish the role it may have played in the prognosis of
GARFIELD-AF patients.
Another limitation is outcomes in HF patients with LVEF
<40% and ≥40%, who were not analysed separately. This
study stratified patients with HF by NYHA functional class
I–IV. However, their European Heart Rhythm Association
score of AF was not measured; hence, disabilities attributable
to these two disease conditions were not differentiated. We
were therefore unable to analyse this cohort according to a
combination of NYHA and European Heart Rhythm Associa-
tion scoring. As in all registries, patients were not randomly
enrolled to treatments. Also, adverse event recognition
was left at investigators’ judgement, and not centrally
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adjudicated—although to minimize errors, a sizable propor-
tion (20%) of eCRFs were audited. Finally, it is possible that,
in addition to the extensive collection of ancillary data, other
variables that were not measured could have further refined
interpretation of the findings.
Conclusions
The present analysis of a very large, contemporary,
multi-country registry shows that patients with HF and newly
diagnosed AF are treated similarly to those with AF and no HF
in terms of anticoagulation; yet they remain a higher-risk
group with respect to stroke/SE, all-cause death, and cardio-
vascular death than no-HF patients. AF confers a relatively
low risk of developing HF or worsening HF already present.
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